Accessibility Menu
UroGen Pharma Stock Quote

UroGen Pharma (NASDAQ: URGN)

$17.99
(-0.8%)
-0.15
Price as of October 22, 2025, 11:39 a.m. ET

KEY DATA POINTS

Current Price
$17.99
Daily Change
(-0.8%) $0.15
Day's Range
$17.9 - $18.55
Previous Close
$18.14
Open
$18.27
Beta
0.97
Volume
5,613
Average Volume
1,169,460
Market Cap
839.2M
Market Cap / Employee
$18.14M
52wk Range
$3.42 - $21.71
Revenue
-
Gross Margin
0.89%
Dividend Yield
N/A
EPS
-$3.32
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

UroGen Pharma Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
URGN+44.89%-11.38%-2.39%+29%
S&P+15.06%+95.03%+14.29%+182%

UroGen Pharma Company Info

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$24.22M10.8%
Gross Profit$20.67M5.3%
Gross Margin85.34%-4.5%
Market Cap$631.67M-8.5%
Market Cap / Employee$2.69M0.0%
Employees23516.9%
Net Income-$49.94M-49.5%
EBITDA-$40.85M-59.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$93.99M-57.4%
Accounts Receivable$19.65M12.8%
Inventory7.1-4.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$125.92M28.2%
Short Term Debt$1.55M94.5%

Ratios

Q2 2025YOY Change
Return On Assets-63.18%-3.0%
Return On Invested Capital-584.70%-10.6%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$40.36M-72.7%
Operating Free Cash Flow-$40.22M-72.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book17.2517.61-53.06-13.59-10.00%
Price to Sales6.135.545.716.94-4.51%
Price to Tangible Book Value17.2517.61-53.06-13.60-10.00%
Enterprise Value to EBITDA-24.28-14.19-12.46-15.26-17.83%
Total Debt$122.75M$124.92M$126.36M$127.47M28.71%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.